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ARTICLE INFO ABSTRACT
Lymph node status has been considered as an important prognosticindicator for
survival in breast cancer. Recently the need for axillary clearanceand the
signiﬁcance of performing sentinel node biopsy has been questioned.
Despite this, sentinel lymph node biopsy is considered as a standard method of
assessment of clinically node-negative breast cancers. Economicimplications as
well as patient related factors have led to the development a number of intra-
operative techniques. Review of the emerging trends of practice in the last 4 years
show that although routine histological examination remains the gold standard in
most centres, intraoperative assessment remains the most favourable, timely and
cost-eﬀective option to analyse sentinel nodes.
Molecular techniques appear to be far more superior to other histological tests
such as frozen section or touch imprint cytology. Emerging research suggests that
molecular techniques can be used to predict the presence of nonsentinel node
metastasis. As a result, this technique may be a reliable surrogate to evaluate
axillary tumor burden.
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Introduction
Lymph node status remains an important
prognostic indicator for survival in breast cancer
although other prognostic markers recently gaining
importance in directing the adjuvant treatment
pathway. Sentinel lymph node biopsy has become a
1
standard method of assessment of clinically node-
negative breast cancers, with delayed axillary
clearance as a second procedure, if positive.
Economic implications in terms of bed occupancy
and duration of hospital stay2, technical diﬃculties,
being a more challenging procedure and patient-
related factors, including stress and exposure to a
second general anaesthesia have led to the
development a number of intraoperative techniques
for the evaluation of sentinel nodes. Most of these
are now clinically implemented with varying
degrees of success to reduce second procedure rates.
Layﬁeld comprehensively discussed theet al.
intraoperative methods in use in 2011. The
3
following review of the literature examines the
intraoperative methods for evaluation of sentinel
lymph nodes, emerging trends with comparison of
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the national guidelines of the United Kingdom and
the United States in the last 4 years for intraoperative
evaluation of sentinel lymph nodes.
Current practice
Intraoperative methods of assessment in
useinclude frozen section ( ), touch imprintFS
cytology ( ), rapid immunocytochemistry andTIC
one-step nucleic acid ampliﬁcation ( ) usingOSNA
both whole node and half node analysis methods.
One of the commercially available reverse
transcriptase based assay ( - ) which was inRT PCR
use, had been withdrawn due to ﬁnancial problems of
the manufacturer. However a new version, known as
4
Metasin is being developed.
4,5
In addition, Scanning elastic scattering spectro-
scopy ( ), a technology still in development isESS
reviewed. While frozen section has been previously
cited as the most commonly used technique, the
advent of molecular assays has resulted in increasing
numbers of centres now beginning to adopt this
process for intraoperative assessment. Currently 20
3
centres in the and 180 centres in the EuropeanUK
Unionare using this technology according to
Sysmex , the commercial manufacturer. However it
®
has not been marketed in the United States.
Frozen section
This technique involves sending the whole or part
of the sentinel lymph node to the pathologist who
freezes the tissue. It is then sectioned at 6μm or less
and microscopically examined after being subjected
to H&E staining. While protocols for this method
vary in the published studies, a metaanalysis in 2011
of 47 studies involving 13,062 patients using this
method showed that the overall sensitivity was
60.6% with a speciﬁcity of 100%. However, had
6
FS
a much lower sensitivity in detecting micro-
metastases and isolated tumor cells compared with
macro-metastases and the diﬀerence was statistically
signiﬁcant (28.9% vs 80.3% P< 0.001). The authors
concluded that this method lacked the accuracy
required to rule out micro-metastases. It has been
demonstrated that sentinel lymph node biopsies
which only yield micro-metastases and isolated
tumor cells are nevertheless associated with a non-
sentinel node involvement rate of 20% and 12%
respectively when axillary clearance is subsequently
performed. Therefore, sole use of this method
7,8
would result in a small but not insigniﬁcant false
negative assessment. The requires a dedicatedFS
team in pathology comprising a biomedical scientist
and pathologist available for assessment when
required. In addition, it is dependent on the skills and
experience of the pathologist interpreting the
section. All of these factors make it an expensive
option in terms of cost eﬀectiveness. A summary of
FS is shown in Table 1 and Figure 1.
Touch imprint cytology
TIC or scrape cytology are performed by
pressing or scraping the cut surface of the sentinel
lymph node onto a slide. This imprint is then stained
and examined. In a meta-analysis of 31 studies
involving 4438 patients in 2005, Tew showedet al
that there was disparity in protocols, as well as
intraoperative and histological technique. Clear
9
comparison and pooled interpretation of the studies
therefore should be done with caution. Nevertheless
the estimate of overall sensitivity of was 63%TIC
and speciﬁci ty 99%. Subsequently, other
45
Table 1. Summary of frozen section and touch imprint cytology
Technique Sensitivity Speciﬁcity Advantage Disadvantage
Frozen section
Tissue is frozen and
sectioned at 6μm and
H&E stained
Touch imprint cytology
Scrape of lymph node
surface stained and
examined
Established
intraoperative
assessment tool
Less expensive
compared to FS
with no loss of
tissue
Low sensitivity in identiﬁcation
of micro-metastases/isolated
tumor cells
Sensitivity varies with technique
and low sensitivity to macro-
metastases
60.6%
(macro-
metastases)
63%
100%
(macro-
metastases)
99%
Abbreviation: : frozen sectionFS
Figure 1. Frozen section histology of a malignant .SLN
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authors have also demonstrated that sensitivity
varies not just with the speciﬁc technique used, but
also depends on the size of the metastasis; with low
sensitivity in the presence of micro-metastases
compared to standard histological examination
(22% for micro-metastases compared to 81% for
macro-metastases). The advantage of this
9-14
technique over is that it is less expensive and timeFS
consuming with no loss of tissue. However
interpretation of this technique requires experienced
cyto-pathologists and if the result is equivocal there
is no clear guidance regarding subsequent
management. Moreover, lobular cancers are more
diﬃcult to identify using this technique due to
overlapping morphological features with lymphoid
tissue. The use of immunocytochemical techniques
used in conjunction with has been shown toTIC
improve the recognition of both of these entities but
its use needs to be balanced against the additional
time required to perform this test and the
costeﬀective- ness of implementing this as part of
intraoperative diagnosis. A summary of isTIC
shown in Table 1 and Figure 2.
Molecular techniques: one-step nucleic acid
amplification ( )OSNA
The development of molecular assays for
intraoperative detection of nodal metastases has
helped to address the issue of detection of
micrometastases. Two types of molecular assays
have been developed. Firstly, an intraoperative real-
time quantitative polymerase chain reaction ( -RT
PCR) assay was developed commercially by
Genesearch which used dual m markers
TM
RNA
( 19 and mammaglobin). For commercialCK
15
reasons this assay was withdrawn. However, an
alternative assay called Metasin using the same
m markers has recently been assessed inRNA
comparison to the Genesearch assay and histology
TM
as the gold standard. The sensitivity and speciﬁcity
5
of Metasin compared to the Genesearch was 95%
TM
and 97%, respectively. Metasin was concordant with
Genesearch in 148/154 lymph node homogenates
TM
and its positive predictive value was 90% and
negative predictive value 97% for both histology and
Genesearch . This suggests that the Metasin assay
TM 5
is a viable replacement and a valuable assay in
intraoperative diagnosis of sentinel nodes. The other
molecular assay in use utilises , developed byOSNA
Sysmex , utilised Ck19 alone as a marker. The
® 16
result is regarded as "negative" for m copyRNA
numbers below 250/μl, [1+] for copy numbers
between 250- 5000/μl (suggestive of micro
metastases) and [2+] if greater than 5000/μl
indicating macrometastases. is anO S N A
established technique validated by a number of
studies. Combined analysis of 9 studies involving
16-23
3631 samples by Cserni in 2012 showed anet al.
overall sensitivity of 91.7%, speciﬁcity of 97%,
accuracy of 96.1% and positive predictive value
( ) 85.8% with negative predictive valuePPV
( ) of 98.3%. There was close concordanceNPV
6
among these studies. The high negative predictive
value for compares favourably with otherOSNA
methods of assessment. Direct comparison between
OSNA FS OSNAand showed that detected more
sentinel lymph node metastases particularly micro-
metastases. This is because results reﬂect
24
OSNA
the status of the whole processed lymph node, while
both and are based on the analysis of the cutFS TIC
surface of the lymph node slices. These slices may be
1.5 to 2 mm thick and the unexamined tissue may
potentially harbour a metastatic or more commonly,
a micro-metastatic deposit. has theOSNA
advantage that it does not require puriﬁcation of
m and therefore is a quicker method comparedRNA
to - . The additional advantage is that it is anRT PCR
25
automated method requiring a trained lab technician
with a relatively quick turnaround time when the
whole node is processed.
Following the publication of these studies, which
used half node analysis for validation of their results,
most centres where this technology is available carry
Figure 2. Aof sentinel lymph node: ) NormalTIC
sentinel node with lymphocytes and tangible body
macrophages containing blue dye, ) withB SLN
metastatic deposit on .TIC
A
B
46 Banerjee, . Arch Breast Cancer 2014; Vol. 1, No. 2: 44-52et al
Intra-operative assessment of sentinel lymph nodes
describes the process using 50% nodeOSNA
analysis.
Elastic scattering spectroscopy ( )ESS
This method was developed for rapid detection of
metastases within sentinel lymph nodes using a point
contact technique that collects broadband optical
spectra sensitive to absorption and scattering within
the tissue. While the full potential of this
30
technology has yet to be realised, the initial
assessment of its detection of clinically relevant
metastases showed a sensitivity of 69% speciﬁcity of
96%. This compares well with and and
30
FS TIC
does not require a specialized pathologist for
interpretation. The proponents of this technology
aim to increase its sensitivity without loss of
speciﬁcity by improved scanning techniques as well
as developing more advanced scanning hardware
which will reduce scanning time. As no commercial
partner has come forward yet the cost eﬀectiveness
has not been assessed.
National Institute of Clinical Excellence
( guidelines ) 2013 and /NICE UK NCCN ASCO
recommendations
The guidelines (http://www.nice.org.uk),NICE
state that pathological methods that can be used
intraoperatively include and . However, inFS TIC
practice these intraoperative methods may have
relatively low accuracy particularly in inexperie-
nced hands. For molecular analysis of sentinel
nodes, recommends whole lymph nodeNICE
analysis using the -100i system as anRD OSNA
option for detecting sentinel lymph node metastases
during breast surgery in people with early invasive
breast cancer who require a sentinel lymph node
biopsy, and in whom axillary lymph node dissection
will be considered. The Metasin test is not yet
recommended for detecting sentinel lymph node
metastases in patients with early invasive breast
cancer in routine clinical practice. However,NHS
the guidelines concede
that the Metasin test shows promise and the
development of robust evidence is recommended to
demonstrate its utility in clinical practice.
out whole node analysis. While 19 expression isCK
high in most breast cancers, the prevalence of 19CK
negative cancers is estimated by studies to range
between 1-3% in unselected series. Special sub-
26
types of cancers as well as triple negatives and
luminal A have been reported to show a higher
prevalence of 19 negative cancers while oneCK
study has suggested that older patients may also
show a higher prevalence. The potential risk of
27,28
whole node analysis is that in a small proportion of
patients may be falsely reassured by a negative
OSNA result and subsequently not receive
appropriate adjuvant therapy. Although lymph node
status is not the only prognostic indicator, and its
importance has decreased in terms of prognostic-
ation and treatment planning, identiﬁcation of 19CK
negative cancers preoperatively may reduce the risk
of a false negative result and avoid under-treatment
of loco-regional disease.
Cost– beneﬁt analysis comparing withOSNA
conventional histopathological evaluation show that
although the duration of the ﬁrst surgery waslonger
in the group, the number of admission daysOSNA
overall was reduced and resulted in a lower average
cost of surgery with a mean saving of €439.67 per
patient. However it must be acknowledged that
29
there is an initial cost to set up the service and train
staﬀ to appropriately use the technology. In some
institutions this could be prohibitive due to
limitations of resources and their rationing. In our
experience the analysis of up to 2 nodes by OSNA
requires 40 -60 minutes with additional time for
more than 2 nodes. In our practice once the sentinel
node biopsy is performed the time required for
analysis coincides with the time either breast
conserving surgery or mastectomy is occurring. The
results often become available as the wounds are
being closed so in reality, increase in operative time
occurs rather infrequently. If the result is positive
additional time will be required for axillary node
dissection,
nd this needs to be considered in theatre time
planning and allocation but this would be required
for all methods of intraoperative assessment. Table 2
asummaries the molecular techniques and Figure 3
Table 1. Summary of molecular techniques
Technique Sensitivity Speciﬁcity Advantage Disadvantage
Genesearch
TM
Metasin
OSNA
90%
95%
91%
97%
97%
97%
Dual m markers used. AutomatedRNA
procedure not requiring additional pathologist
time. Quick turnaround time
No longer availabl
Not yet approved by
for other thanNICE
research
Single m markerRNA
19 (which a smallCK
minority of breast
cancer may not
express).
Dual m markers. Automated procedureRNA
not requiring additional pathologist time used.
Quick turnaround time
Does not required m puriﬁcation.RNA
Automated procedure not requiring additional
pathologist time. Quick turnaround time.
Approved by NICE
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based on 0010a multicentre study overASCOGZ
eight years which concluded that since metastases,
which were no detectable by H&E stain technique,
do not have signiﬁcant impact on survival, -RT PCR
routine use could not be recommended instead of
H&E staining. No consideration is given to whole
node or half node analysis in this study.
In contrast to these guidelines the National
Comprehensive Cancer Network ( )N C C N
guidelines and the American Society of Clinical
Oncology ( ) continue to endorse H&EASCO
staining with histological evaluation as the gold
standard and despite the evidence presented have not
amended their recommendations to date to include
molecular techniques. These recommendations are
Table 3. Summary of intraoperative techniques in use for evaluation of sentinel lymph nodes
Technique Sensitivity/
Speciﬁcity
NCCN ASCO/
guidelines
Figure 3. C,D,E F, G) The slices to be assessed by are homogenized and centrifuged and the supernatant drawn oﬀ. ) It isOSNA
added to reagents that facilitate the Loop mediated isothermal ampliﬁcation ( ) and then placed in the processor forRT LAMP
ampliﬁcation. The result is displayed as a measure of turbidity, as m copy number value and assessed as positive or negative.RNA
Advantages Disadvantages
NICE
guidelines
( )UK
FS
TIC
-RT PCR
OSNA
60.6 % sensitivity;
100% speciﬁcity
63% sensitivity;
99% speciﬁcity
90-95% sensitivity;
97% speciﬁcity
91% sensitivity;
97% speciﬁcity
Established intra-
operative technique
Cheaper than FS
Dual m RNA
markers. Quick –
turn around time.
Automated process
with additional
pathologist time
required.
Quick turn-around
time no puriﬁcation
required so faster
than -RT PCR
Automated process
without additional
pathologist time
required.
Low sensitivity for
micro-metastases.
expensive
Low sensitivity for
micro-metastases.
Operator dependent
No commercial
availability yet.
Single m markerRNA
19 not expressedCK
by all breast cancers
Can be used but Not
recommended for routine
practice
Can be used but Not
recommended for routine
practice
Not approved for routine
practice
Approved for routine
practice with whole node
analysis recommended
while half node analysis
with histopathology to
be performed according
to clinical judgment
Not approved for
routine practice
Not approved for
routine practice
Not approved for
routine practice
Not approved for
routine practice
Abbreviations: : Frozen section; : Touch imprint cytology; : One step nucleic Acid AmplificationFS TIC OSNA
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results showed that in this trial, axillary radiation
was a comparable alternative to axillary node
dissection with less morbidity associated with
lymphodema. The authors have suggested that
knowledge of the number of lymph node metastases
was not necessary in the decision to administer
adjuvant systemic treatment, however the results of
this trial have not yet been validated. In addition, the
trialists acknowledge that it is underpowered to
demonstrate non inferiority due to the low number of
events with recurrence of axillary dissection at 10
years at 0.43% compared to 1.19% with axillary
radiotherapy. In March 2014, updated itsASCO
recommendations regarding sentinel node biopsy.
38
There is now recommendation for greater selectivity
in oﬀering patients axillary surgery. Patients who
plan to have breast conserving surgery with whole
breast radiotherapy and have 2 or less metastatic
nodes are advised not to have axillary clearance.
Most patients undergoing mastectomy are still
recommended to have sentinel node biopsy followed
by axillary clearance if metastases are present.
However, patients with large or locally advanced
cancers, inﬂammatory cancers, where breast
conserving surgery is planned are recommended not
to have a sentinel node biopsy. Upfront axillary
dissection is implied for large/locally advanced
tumors. Patients with (even in the case of highDCIS
grade disease) are advised not undergo any form of
operative axillary assessment. These changes have
yet to be endorsed by ( ).Our currentNICE UK
practice is to oﬀer sentinel node biopsy to patients
who do not have evidence of lymph node
involvement at triple assessment in the presence of
an invasive cancer or high grade ductal carcinoma in
situ ( ). In these cases, is performedDCIS OSNA
intraoperatively. Axillary clearance is only
performed if the test is positive or isOSNA
subsequently histopathology shows evidence of
metastasis.
However, it is clear that the trend in the future is
for performing fewer axillary dissections and
perhaps the need to perform sentinel node biopsy
maybe called into question. Currently the decision-
making tool for axillary dissection is still sentinel
node biopsy and intraoperative assessment allows
further streamlining of this process.
Although routine histological examination
remains the gold standard in most centres in
assessing sentinel lymph node status, there are
several disadvantages, the most critical is the time
needed to produce a result (average 48 hours). In
addition, there is considerable variation between
centres regarding the method and extent to which
these lymph nodes have to be histologically
examined. For example, there are diﬀerences in
relation to the initial slicing of the node; the ASCO
guidelines recommend slicing through the long axis
whereas Pathology Reporting of BreastNHSBSP
Discussion
Despite the publication of the results of the
ACOSOG Z0011 trial, which questions the need to
perform axillary node dissection after positive
sentinel node biopsy, investigation of the status of
the sentinel node biopsy still remains the most
accurate way to predict axillary nodal involvement;
an important and critical prognostic indicator of
survival. The trial demonstrated that in patients with
small primary tumors (T1-T2) and a clinically
negative axilla, performing sentinel node biopsy
alone did not result in a worse survival outcome
compared with patients who had undergone axillary
node dissection for limited sentinel node
metastases. However, these results cannot be
31
extrapolated to the treatment of all breast cancers,
not only because they do not include patients with
higher stage disease but because the protocol
showed that there was insuﬃcient blinding of the
sentinel node biopsy result from the oncologists,
who subsequently treat the patients with chest wall
radiotherapy. With the knowledge of positive
sentinel node, it is possible that tangential ﬁelds may
have been used to irradiate the axilla. The
implication is that the outcome from this trial should
thus be interpreted with caution because of the
possibility of treatment of potentially positive
axillary nodes with radiotherapy artiﬁcially
improving the outcome. Retrospective analysis had
already shown that 16.4- 20.8% of sentinel node
positive patients did not continue to have an axillary
node dissection. The trend may be related to the
32,33
decision to perform breast conserving surgery with
adjuvant radiotherapy to the breast with angential
ﬁelds covering the axilla. The role of axillary nodal
34
radiation following surgery with or without axillary
node clearance ( ) has been explored by theANC
NCIC CTGMA 20 trial in 2011. The results have
suggested that it is associated with increased
morbidity, therefore its role as adjuvant therapy in
node positive patient treated with alone wasSNLB
uncertain according to this study. Following on
35
from this, the 23- 01 study also attempted toIBCSG
investigate the outcome for patients who do not
undergo in the presence of positive sentinelANC
nodes, but continue to have adjuvant treatment.
Unfortunately, this trial has also ended prematurely
with poor accrual and is underpowered but the
preliminary results supports the Z0011 trial
ﬁndings. However these studies do not address the
36
need to accurately evaluate axillary status in order to
assess prognosis and plan appropriate adjuvant
treatment in the majority of breast cancers. The most
recent multicentre trial comparing the use of axillary
radiotherapy with axillary node dissection (EORTC
10981-22023 trial) published its resultsAMAROS
in February 2010. outcome of
37
The ﬁnal analysis of
this trial was presented at the American Society of
Clinical Oncology 2013 ( 2013). TheirASCO
37
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frozen section or molecular diagnosis.
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